New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
07:16 EDTRPRXRepros Therapeutics reports FDA recommends study of Androxal to be completed
Repros Therapeutics provided a clinical update of its Androxal Phase 3 program following receipt of written guidance from the FDA. The FDA has informed Repros to proceed with the analysis of ZA-301 as previously planned, and that data should be evaluated both with and without patients from the high enrolling site where the patients' baseline characteristics appeared different from other sites in the study. Additionally, the FDA accepted Repros' plan regarding study ZA-302 to enroll additional patients. They also noted that Repros should revise the statistical analysis plan and sample size to reflect increased enrollment. Study ZA-302 will also be analyzed with and without patients from the high enrolling site where the patients' baseline characteristics appeared different from other sites in the study.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
19:31 EDTRPRXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Progress Software (PRGS), up 1%. ALSO HIGHER: Repros Therapeutics (RPRX), up 21.9% after announcing acceptance for filing of NDA its enclomiphene citrate product... TCP International (TCPI), up 13.7% after announcing that product validation is proceeding as expected... Intrexon (XON), up 2.4% after signing a CRADA with NCI for RTS platform. DOWN AFTER EARNINGS: Sigma Designs (SIGM), down 2.8%... Micron Technology (MU), down 1.7%. ALSO LOWER: Conatus Pharmaceuticals (CNAT), down 4.4% after filing to sell common stock... TrueCar (TRUE), down 1.8% after being initiated with a Sell at B. Riley... ZIOPHARM Oncology (ZIOP), down 1.8% after filing to sell 11.72M shares of common stock for holders.
16:11 EDTRPRXRepros Therapeutics announces acceptance for filing of NDA
Subscribe for More Information
March 24, 2015
14:18 EDTRPRXRepros Therapeutics April volatility elevated at 144
Repros Therapeutics April call option implied volatility is at 144, May is at 108, August is at 107; compared to its 26-week average of 103 according to Track Data, suggesting large near term price movement

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use